These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 35706081)

  • 41. [Analysis of clinical characteristics of 362 vaccinated or unvaccinated patients infected by novel coronavirus Omicron variant].
    Feng Q; Wang Z; Yu H; Shi L; Xu L
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2022 May; 34(5):459-464. PubMed ID: 35728844
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Post-vaccination infection rates and modification of COVID-19 symptoms in vaccinated UK school-aged children and adolescents: A prospective longitudinal cohort study.
    Molteni E; Canas LS; Kläser K; Deng J; Bhopal SS; Hughes RC; Chen L; Murray B; Kerfoot E; Antonelli M; Sudre CH; Pujol JC; Polidori L; May A; Hammers PA; Wolf J; Spector PTD; Steves CJ; Ourselin PS; Absoud M; Modat M; Duncan PEL
    Lancet Reg Health Eur; 2022 Aug; 19():100429. PubMed ID: 35821715
    [TBL] [Abstract][Full Text] [Related]  

  • 43. SARS-CoV-2 RNA load and detection rate in exhaled breath condensate collected from COVID-19 patients infected with Delta variant.
    Sawano M; Takeshita K; Ohno H; Oka H
    J Breath Res; 2022 Jun; 16(3):. PubMed ID: 35580553
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Increase in Viral Load in Patients With SARS-CoV-2 Delta Variant Infection in the Republic of Korea.
    Kim JM; Rhee JE; Yoo M; Kim HM; Lee NJ; Woo SH; Jo HJ; Kwon D; Lee S; Yoo CK; Kim EJ
    Front Microbiol; 2022; 13():819745. PubMed ID: 35308391
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Analysis of clinical characteristics of 66 pediatric patients with B.1.617.2 (Delta) variant of COVID-19.
    Hao J; Hu XC; Fan MX; Chen J; Cheng QR; Li Z; Hu ZL; Ge XH
    World J Pediatr; 2022 May; 18(5):343-349. PubMed ID: 35287229
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of Clinical Characteristics and Outcome Between Vaccinated and Non-Vaccinated Patients of Covid-19 During the Delta Variant-Dominated Fourth Wave in a Tertiary Care Hospital in Karachi, Pakistan.
    Khan JA; Satti L; Bizanjo M; Ather NA
    Cureus; 2022 Apr; 14(4):e23726. PubMed ID: 35509752
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study.
    McKeigue PM; McAllister DA; Hutchinson SJ; Robertson C; Stockton D; Colhoun HM
    Lancet Respir Med; 2022 Jun; 10(6):566-572. PubMed ID: 35227416
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical outcomes of monoclonal antibody therapy during a COVID-19 outbreak in a skilled nursing facility-Arizona, 2021.
    Dale AP; Hudson MJ; Armenta D; Friebus H; Ellingson KD; Davis K; Cullen T; Brady S; Komatsu KK; Stone ND; Uyeki TM; Slifka KJ; Pérez-Vélez CM; Keaton AA
    J Am Geriatr Soc; 2022 Apr; 70(4):960-967. PubMed ID: 35141874
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Transmission dynamics and epidemiological characteristics of SARS-CoV-2 Delta variant infections in Guangdong, China, May to June 2021.
    Kang M; Xin H; Yuan J; Ali ST; Liang Z; Zhang J; Hu T; Lau EH; Zhang Y; Zhang M; Cowling BJ; Li Y; Wu P
    Euro Surveill; 2022 Mar; 27(10):. PubMed ID: 35272744
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differences in Clinical Characteristics Between Delta Variant and Wild-Type SARS-CoV-2 Infected Patients.
    Hu Z; Huang X; Zhang J; Fu S; Ding D; Tao Z
    Front Med (Lausanne); 2021; 8():792135. PubMed ID: 35047533
    [No Abstract]   [Full Text] [Related]  

  • 52. Delta variant effect on the clinical course of adolescent COVID-19 patients.
    Çağlar HT; Pekcan S; Yılmaz Aİ; Ünal G; Metin Akcan Ö; Ünsaçar MZ; Özdemir M; Akın F
    Pediatr Pulmonol; 2023 Jan; 58(1):115-121. PubMed ID: 36177518
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Regdanvimab improves disease mortality and morbidity in patients with COVID-19: A meta-analysis.
    Yang M; Li T; Jiang L; Wang Y; Tran C; Ao G
    J Infect; 2022 Oct; 85(4):e122-e124. PubMed ID: 35728643
    [No Abstract]   [Full Text] [Related]  

  • 54. Characteristics of Critically Ill COVID-19 Patients in Busan, Republic of Korea.
    Lee J; Son H
    Korean J Fam Med; 2023 May; 44(3):158-167. PubMed ID: 37225441
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Stable nebulization and muco-trapping properties of regdanvimab/IN-006 support its development as a potent, dose-saving inhaled therapy for COVID-19.
    McSweeney MD; Stewart I; Richardson Z; Kang H; Park Y; Kim C; Tiruthani K; Wolf W; Schaefer A; Kumar P; Aurora H; Hutchins J; Cho JM; Hickey AJ; Lee SY; Lai SK
    Bioeng Transl Med; 2022 Aug; 8(1):e10391. PubMed ID: 36248234
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical Time Delay Distributions of COVID-19 in 2020-2022 in the Republic of Korea: Inferences from a Nationwide Database Analysis.
    Shim E; Choi W; Song Y
    J Clin Med; 2022 Jun; 11(12):. PubMed ID: 35743340
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Correction to: A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019.
    Open Forum Infect Dis; 2023 Apr; 10(4):ofad196. PubMed ID: 37089779
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Regdanvimab improves disease mortality and morbidity in patients with COVID-19: Too optimistic and too early to say?
    Marcec R; Dodig VM; Likic R
    J Infect; 2023 Jan; 86(1):66-117. PubMed ID: 36341992
    [No Abstract]   [Full Text] [Related]  

  • 59. Effect of Regdanvimab on Mortality in Patients Infected with SARS-CoV-2 Delta Variants: A Propensity Score-Matched Cohort Study.
    Hwang S; Lee NY; Nam E; Kim YK; Kim SW; Chang HH; Kim Y; Bae S; Jeong J; Shin JH; Jang G; Lee C; Kwon KT
    Infect Dis Ther; 2024 May; 13(5):1037-1050. PubMed ID: 38607524
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness of regdanvimab treatment for SARS-CoV-2 delta variant, which exhibited decreased
    Kim H; Jang YR; Lee JY; Ko JH; Lee JY; Cho S; Lee YD; Song J; Hyun M; Kim HA; Hwang S; Ryou S; Na YJ; Lee JY; Lee C; Lee NY; Shin S; Kwon KT; Kim JY; Peck KR
    Front Cell Infect Microbiol; 2023; 13():1192512. PubMed ID: 37256107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.